Indian Billionaire's Temple Wearable Faces Medical Community Backlash
Doctors challenge the scientific validity of a high-priced brain blood-flow tracking device.
1Controversial Wearable Launch
Entrepreneur Deepinder Goyal has launched Temple, a US$907 wearable device designed to track brain blood flow and thermal metrics. Despite its high price point and endorsements from elite Indian athletes like Shubman Gill, the product has triggered intense scrutiny from the medical community regarding its actual physiological measurement capabilities.
2Medical Community Skepticism
Prominent doctors, including hepatologist Cyriac Philips and nephrologist Sanjeev Bagai, have publicly labeled the device a health scam and a gimmick. Critics argue that the product lacks peer-reviewed research to support its bold claims, urging regulatory bodies to intervene and investigate the device's marketing practices and health data accuracy.
3Technical Validity Concerns
Physicians point out that measuring brain blood flow via optical sensors on the temple is physiologically complex. Experts suggest the device likely only captures data from the superficial temporal artery, which supplies blood to the face and skin, rather than providing accurate insights into internal cerebral blood circulation patterns.
4Founder's Strategic Defense
Deepinder Goyal defends Temple as a fitness and wellness device rather than a medical instrument. He maintains that the metrics provided are based on emerging science and that further research is currently underway. The company acknowledges that certain future features may eventually require formal regulatory approval as they expand capabilities.
5Regulatory Gray Areas
The debate highlights a growing tension between consumer wellness gadgets and medical-grade technology. Similar to recent FDA warnings issued to companies like Whoop regarding blood-pressure features, the industry faces increasing pressure to distinguish between general fitness tracking and diagnostic medical tools that require rigorous clinical validation and official clearance.
6Corporate Background Context
Deepinder Goyal, the 43-year-old co-founder of the food-delivery giant Zomato, stepped down as CEO in 2026 to focus entirely on Temple. The startup successfully raised US$54 million in February, achieving a valuation of approximately US$190 million, and has reportedly secured orders from customers across more than 62 different countries.
7Advisory Board Credentials
Despite the ongoing criticism from local doctors, Temple maintains an advisory board that includes professors from Harvard and the University of Ottawa. The company claims these academic partnerships support their development of new metrics, though they have not yet provided the specific peer-reviewed evidence requested by the skeptical medical community.
8Future Product Roadmap
Temple is currently expanding its feature set to include detection for conditions such as snoring and jaw clenching. As the company continues its global rollout, the primary challenge remains balancing rapid consumer adoption with the necessity of proving its health-tracking claims to satisfy both medical regulators and the scientific community.